相关实验视频
Updated: May 12, 2026

08:36
Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
Published on: April 7, 2023
940
第3期,多中心,随机,双盲,安慰剂控制,平行组对Takayasu动脉炎患者的ustekinumab进行研究
Hajime Yoshifuji1, Tomonori Ishii2, Hiroki Ohashi3
1Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Rheumatology advances in practice
|March 19, 2025
概括
这项研究评估了乌斯特基努马布用于塔卡亚苏动脉炎,但由于招聘问题而提前停止. 无法确定有效性,尽管没有出现乌斯提金巴的新安全问题.
科学领域:
- 免疫学 免疫学 免疫学
- 类风湿病学 类风湿病学
- 血管生物学 血管生物学
背景情况:
- 塔卡亚苏动脉炎 (TAK) 是一种罕见的慢性大血管血管炎,具有显著的未满足治疗需求.
- 当前的标准护理通常涉及皮质类固醇,这可能会产生严重的副作用.
研究的目的:
- 评估乌斯特基努马布 (UST) 的疗效,安全性,药理动力学和免疫性,对日本TAK患者进行评估.
- 评估UST作为这种罕见的血管炎新型治疗选择的潜力.
主要方法:
- 一个第三阶段,双盲,随机对照试验,比较UST与安慰剂在TAK患者.
- 患者接受了协议定义的口服葡萄糖皮质激素逐渐减少的治疗方案,并与UST或安慰剂一起使用.
- 主要终点是双盲阶段TAK复发的时间.
主要成果:
- 该研究因患者招募的挑战而提前结束,未能达到预先确定的样本大小.
- 有限的数据显示,UST的中位时间到复发为11.14周,安慰剂为12.64周 (HR=1.86).
- 没有发现UST的新安全信号;严重的不良事件很少发生,并且大多与研究干预无关.
结论:
- 由于早期终止和样本规模不足,无法充分评估乌斯特基努马布在塔卡亚苏动脉炎中的疗效.
- 乌斯特基努马布在该患者群体中表现出可接受的安全性,没有发现新的安全问题.
相关概念视频
Clinical Trials
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Asthma III: Clinical Manifestations
Asthma presents with a characteristic pattern of episodic respiratory symptoms that reflect underlying airway inflammation, bronchoconstriction, and mucus hypersecretion. Although severity varies among individuals, certain clinical manifestations are considered hallmarks of the disorder and often guide diagnosis and assessment.Respiratory SymptomsA persistent cough is one of the most common early features of asthma. It is frequently dry and tends to worsen at night or in the early morning,...

